Artemis Medicare Services Ltd Q2 FY26 – The Gurgaon Hospital That Runs on Scalpel, IFC Money, and Surgical Precision (Literally)
1. At a Glance
Welcome to Artemis Medicare Services Ltd (NSE: ARTEMISMED | BSE: 542919) — where heart surgeries, oncology treatments, and corporate finance are all performed with surgical precision.
Q2 FY26 brought in a 15% revenue jump to ₹270 crore and a profit surge of 32.8% to ₹30 crore, proving that sometimes, medicine is good business. The stock, meanwhile, trades at ₹269, giving it a market cap of ₹3,744 crore, or roughly the price of one hospital tower in Gurgaon.
P/E: 39.3
ROE: 12.9%
ROCE: 14.9%
Debt-to-Equity: 0.31
Operating Margin: 16.6%
PAT Margin: 9.1%
Promoter Holding: 66.5% (but 44.5% of that pledged — the financial version of “trust issues”).
Q2 headlines were dramatic: 18.96 million new shares allotted to IFC after conversion of CCDs worth ₹330 crore, Tower III fully operational, and a ₹550–600 crore Delhi hospital expansion plan signed.
In the spirit of the Bhagavad Gita: “You have the right to perform your duty, but not to the fruits thereof.” Artemis seems to have taken it literally — they perform surgeries, the fruits (profits) are sweet, and the duty continues 24×7.
2. Introduction
If Apollo Hospitals is the emperor, Artemis is the prince quietly building its own kingdom — one surgical ward at a time. Born in 2004 and promoted by the Apollo Tyres Group, this Gurgaon-based healthcare chain runs one of the country’s most advanced super-specialty hospitals, attracting both NCR’s elite and international medical tourists.
Their flagship 700-bed hospital (up from 489) isn’t just a hospital; it’s practically a city-state of doctors, diagnostics, and desperate relatives clutching credit cards. The company’s latest quarter shows that even as healthcare inflation rises, Artemis is scaling with grace.
Over 98,000 patients visited in Q1 FY26, 4,040 surgeries were performed, and the hospital’s Average Revenue Per Occupied Bed (ARPOB) stood at ₹83,900 — proving that medicine in Gurgaon costs about as much as a weekend in Maldives.
The story gets even better: new towers, asset-light expansions in Raipur, a major entry into Delhi via VIMHANS, and deep involvement in India’s “Heal in India” initiative for inbound medical tourism.
In short: they’re doing surgery on your wallet and on patients, both successfully.
3. Business Model – WTF Do They Even Do?
At its core, Artemis Medicare Services Ltd (AMSL) is a high-end multi-specialty hospital chain providing tertiary and quaternary healthcare services — the complicated stuff where Google and homeopathy can’t help.
Their operations revolve around three key pillars:
700+ beds, 12 centers of excellence, and 40+ specialties.
Strong in oncology, cardiology, neurology, orthopaedics, nephrology, and critical care.
Serves 1 lakh+ patients a quarter with 61% occupancy (clearly, Gurgaon folks are keeping doctors busy).
2. Adjacent Ventures:
Artemis Lite: A short-stay, boutique care model for smaller cities — essentially the “WeWork” of hospitals.
Daffodils by Artemis: A luxury mother-and-child brand where birth comes with business-class treatment.
Artemis Cardiac Care (ACC): A JV with Philips Medical Systems Netherlands BV to operate cardiology centres in Tier-2/3 cities — because heart attacks aren’t just for metro residents.
3. Asset-Light Expansions:
New hospitals managed via O&M (Operate & Manage) or JV structures — Raipur, VIMHANS Delhi.
Focus on spreading brand without ballooning debt.
They treat diseases; their balance sheet remains healthy. That’s the kind of synergy med school doesn’t teach.
Commentary: Solid quarter. Strong revenue growth, expanding margins, and PAT ballooning like a post-surgery hospital bill. QoQ EBITDA growth >20% shows Tower III’s new beds are being monetized efficiently.
5. Valuation Discussion – Fair Value Range (Educational)
A. P/E Method:
EPS (annualised): ₹8.6
Industry P/E: 53.7
Apply conservative range: 30x–45x
👉 Fair Value Range = ₹260 – ₹390/share
B. EV/EBITDA Method:
EV: ₹3,671 crore
EBITDA (TTM): ₹200 crore
EV/EBITDA = 18.4x Peers trade at 16x–22x.
👉 Fair Value Range = ₹3,200–₹4,400 crore → ₹225 – ₹310/share
C. DCF (Simplified): Assume ₹130 crore FCF next year, 15% growth for 3 years, WACC 10%, terminal 3%.
👉 DCF Value = ₹280–₹330/share
🎓 Fair Value Educational Range: ₹260 – ₹350/share (For education only; not a buy/sell recommendation.)
6. What’s Cooking – News, Triggers, Drama
Grab your stethoscopes — Q2 FY26 was anything but dull:
IFC CCD Conversion (Nov 2025): IFC converted 33,000 CCDs (₹1 lakh each) into 18.96 million shares at ₹174.03. The ₹330 crore funding originally earmarked for expansion now partially sits in FDs (₹268 crore parked, ₹62 crore used). Classic hospital cashflow — careful, cautious, clinical.
Tower III Expansion (Gurgaon): Operational from FY25, added 180+ beds focusing on oncology, neuro, and critical care. Now at 700+ total
